Roberta Zappasodi
Overview
Explore the profile of Roberta Zappasodi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
7340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, et al.
Cancer Cell
. 2024 Dec;
43(1):49-68.e9.
PMID: 39642889
T cell-based immunotherapies have demonstrated effectiveness in treating diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) but predicting response and understanding resistance remains a challenge. To address this,...
2.
Verma S, Budhu S, Serganova I, Dong L, Mangarin L, Khan J, et al.
J Clin Invest
. 2024 Sep;
134(17).
PMID: 39225102
Tumor reliance on glycolysis is a hallmark of cancer. Immunotherapy is more effective in controlling glycolysis-low tumors lacking lactate dehydrogenase (LDH) due to reduced tumor lactate efflux and enhanced glucose...
3.
Li J, Chin C, Ying H, Meydan C, Teater M, Xia M, et al.
Nat Commun
. 2024 Apr;
15(1):2879.
PMID: 38570506
Despite regulating overlapping gene enhancers and pathways, CREBBP and KMT2D mutations recurrently co-occur in germinal center (GC) B cell-derived lymphomas, suggesting potential oncogenic cooperation. Herein, we report that combined haploinsufficiency...
4.
Cancila V, Morello G, Bertolazzi G, Chan A, Bastianello G, Paysan D, et al.
Res Sq
. 2024 Apr;
PMID: 38562878
The germinal center (GC) dark zone (DZ) and light zone (LZ) regions spatially separate expansion and diversification from selection of antigen-specific B-cells to ensure antibody affinity maturation and B cell...
5.
Michels J, Venkatesh D, Liu C, Budhu S, Zhong H, George M, et al.
Life Sci Alliance
. 2023 Oct;
7(1).
PMID: 37891002
We previously reported that activation of p53 by APR-246 reprograms tumor-associated macrophages to overcome immune checkpoint blockade resistance. Here, we demonstrate that APR-246 and its active moiety, methylene quinuclidinone (MQ)...
6.
Kang J, Zappasodi R
Trends Cancer
. 2023 Aug;
9(11):911-927.
PMID: 37598003
Immunosuppressive regulatory T cells (Tregs) provide a main mechanism of tumor immune evasion. Targeting Tregs, especially in the tumor microenvironment (TME), continues to be investigated to improve cancer immunotherapy. Recent...
7.
Gregucci F, Spada S, Barcellos-Hoff M, Bhardwaj N, Chan Wah Hak C, Fiorentino A, et al.
Oncoimmunology
. 2023 Jun;
12(1):2222560.
PMID: 37363104
Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However,...
8.
Davar D, Zappasodi R
Oncotarget
. 2023 Jun;
14:614-621.
PMID: 37335294
Glucocorticoid-induced TNFR-related protein (GITR) belongs to the TNFR superfamily (TNFRSF) and stimulates both the acquired and innate immunity. GITR is broadly expressed on immune cells, particularly regulatory T cells (Tregs)...
9.
Kluger H, Barrett J, Gainor J, Hamid O, Hurwitz M, LaVallee T, et al.
J Immunother Cancer
. 2023 Mar;
11(3).
PMID: 36918224
Immunotherapy is the standard of care for several cancers and the field continues to advance at a rapid pace, with novel combinations leading to indications in an increasing number of...
10.
Schreier A, Zappasodi R, Serganova I, Brown K, Demaria S, Andreopoulou E
Front Oncol
. 2023 Jan;
12:1061789.
PMID: 36703796
Triple negative breast cancer (TNBC) is an aggressive disease that is difficult to treat and portends a poor prognosis in many patients. Recent efforts to implement immune checkpoint inhibitors into...